Analyst consensus rating
Gossamer Bio Analyst Rating: Buy
GOSS is rated Buy by 5 analysts with a $1.66 target. As of 2026-08-31.
Direct answer
Gossamer Bio's consensus rating is Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $1.66.
Forecast evidence checked August 31, 2026.
Get free Gossamer Bio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.17
- Average price target
- $1.66
- High price target
- $4.00
- Low price target
- $0.28
- Low target gap
- +64.6%
- Target upside
- +873.5%
- High target gap
- +2,251.6%
- Target range width
- 2,186.9%
- Consensus rating
- Buy
- Analysts
- 5
- Evidence date
- August 31, 2026
- Valid through
- September 7, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Gossamer Bio?
Gossamer Bio has a verified Buy consensus. The same dataset has an average price target of $1.66.
How far are Gossamer Bio's low and high targets from the recorded price?
The low target implies +64.6%, while the high target implies +2,251.6%.
How many analysts are included in Gossamer Bio's consensus?
The verified consensus includes 5 analysts.
How is Gossamer Bio's target upside or downside calculated?
The average target of $1.66 is divided by the recorded price of $0.17, then one is subtracted to produce +873.5%. This does not guarantee a future return.
When was Gossamer Bio's analyst forecast verified?
The data was verified on 2026-08-31. The dataset is valid through 2026-09-07.